- PharmaCielo to begin trading on the TSX Venture Exchange ("TSXV" or "TSX Venture") under the Ticker PCLO at market open today, January 18, 2019.
- In the process of scaling its area under current cultivation from 5.3 hectares of open-air greenhouse (~570,487 ft2) to approximately 20 hectares (~2.15 million ft2) by the end of 2019.
- Approximately 139 hectares (~15 million feet2) of total cultivation capacity, currently.
- Currently producing medicinal grade CBD- and THC-dominant cannabis oil extracts in a temporary facility.
- Expects to complete construction of its 2,300 m2 (24,757 ft2) GMP2 certified Research and Technology Centre oil processing and product innovation facility during Q2-2019.
- Positioned to begin scale distribution and sales during 2019.
- Well-capitalized to execute 2019 objectives, with $31.4 million USD in cash.1
TORONTO, Jan. 18, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil (PharmaCielo Colombia Holdings S.A.S.), will be opening the TSX Venture Exchange ("TSXV") today, on the Company's first day of trading under the symbol "PCLO" as announced January 9, 2019.
David Attard, CEO of PharmaCielo commented, "2019 will be an exciting year for PharmaCielo shareholders. We have constructed a platform with the sophistication and scale to rapidly become a value-added provider of cannabinoid inputs to some of the world's largest organizations. Global, consumer-facing companies are accustomed to supply chain partners that can provide inputs of consistently high quality, in large volume. As the most sophisticated and scalable cannabis producer in South America, PharmaCielo is ready to meet these requirements and to create significant value for shareholders and partners, in the process."
Attard continued, "We are on strong footing as we launch scale production and sales in 2019. The Company is already producing medicinal-grade cannabis oil, is well capitalized and has near-term revenue opportunities both in Colombia and target international jurisdictions."
During fiscal 2019, PharmaCielo will focus on:
- Scaling the Company's area under current cultivation from 5.3 hectares of open-air greenhouse (~570,487 ft2) to approximately 20 hectares (~2.15 million ft2);
- Completion of its 2,300 m2 (24,757 ft2) GMP2 certified Research and Technology Centre oil processing and product innovation facility;
- Receipt of registration from the Colombian Ministry of Agriculture for multiple cannabis strains – confirming unrestricted ownership of unique plant genetics for mass cultivation and oil extraction;
- Commencement of cannabis oil product sales in key markets for revenue generation;
- Confirming agreements with Colombian distributors and end-product manufacturers, to bring consumer products to market;
- Finalizing relationships with distributors and end-product manufacturers in select international jurisdictions, to bring products to market;
- Receipt of ISO 9001 certification for quality management systems (QMS), confirming operational veracity without review for customers;
- Opening of the Company's first bannered Clínica co-located with Centro Oncológico de Antioquia (COA), part of an oncology practitioner network with complementary objectives focused on treatment of 5 million patients.
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, "expects", "is expected", "intends", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be achieved. Forward-looking statements include statements with respect the Listing, completion of construction of the Research and Technology Centre oil processing and product innovation facility, timing of revenue generated from the sale of cannabis, expansion of cultivation capabilities, completion of the Transaction with UBIQUO, opening additional UBIQUO clinics, and developing business relationships domestically and internationally. Forward-looking statements are based on assumptions, including with respect to PharmaCielo's planned products, and the ability to execute its business plan that management believes are reasonable in the circumstances, but the actual results, performance or achievements of PharmaCielo's business may be materially different from any future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, the equity markets generally, risks associated with early stage companies, risks associated with the regulation of cannabis and cannabinoid derivatives, failure to obtain necessary TSXV approval, competition for PharmaCielo's planned products, risks associated with operating in Colombia, and currency exchange risk. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
December 31 2018
GMP (Good Manufacturing Practices) as defined by the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations
For further information: www.PharmaCielo.com; Media Relations: Gal Wilder, Cohn Wolfe, +1.647-259-3261, firstname.lastname@example.org; Investor Inquiries: Investors@pharmacielo.com